Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.
acute myeloid leukaemia
cytochrome
drug-drug interaction
midostaurin
voriconazole
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
20
03
2023
received:
16
01
2023
accepted:
25
03
2023
medline:
19
6
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
Midostaurin is often prescribed with azole antifungals in patients with leukaemia, either for aspergillosis prophylaxis or treatment. Midostaurin is extensively metabolized by cytochrome (CYP) 3A4. In addition, it inhibits and induces various CYPs at therapeutic concentrations. Thus, midostaurin is associated with a high potential for drug-drug interactions (DDIs), both as a substrate (victim) and as a perpetrator. However, data on midostaurin as a perpetrator of DDIs are scarce, as most pharmacokinetic studies have focused on midostaurin as a victim drug. We report a clinically relevant bidirectional DDI between midostaurin and voriconazole during induction treatment. A 49-year-old woman with acute myeloid leukaemia developed invasive pulmonary aspergillosis after induction chemotherapy. She was treated with voriconazole at standard dosage. Six days after starting midostaurin, she developed visual hallucinations with a concurrent sharp increase in voriconazole blood concentration (C
Substances chimiques
Voriconazole
JFU09I87TR
Antifungal Agents
0
midostaurin
ID912S5VON
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2304-2308Informations de copyright
© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Accessed March 9, 2023. https://www.medicines.org.uk/emc/product/9134/smpc/print#INDICATIONS
Food and Drug Administration. Accessed January 13, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000ClinPharmR.pdf
Brüggemann RJ, Verheggen R, Boerrigter E, et al. Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematol. 2022;9(1):e58-e72. doi:10.1016/S2352-3026(21)00232-5
Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol. 2013;72(6):1223-1234. doi:10.1007/s00280-013-2287-6
Menna P, Salvatorelli E, Del Principe MI, et al. Choosing antifungals for the midostaurin-treated patient: does CYP3A4 outweigh recommendations? A brief insight from real life. Chemotherapy. 2021;66(1-2):47-52. doi:10.1159/000513989
Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association [published correction appears in lancet Haematol. 2022 Jun;9(6):e398]. Lancet Haematol. 2022;9(5):e361-e373. doi:10.1016/S2352-3026(22)00073-4
Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-3230. doi:10.1093/jac/dky286
Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166-197. doi:10.1097/FTD.0000000000000952
Decosterd LA, Rochat B, Pesse B, et al. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother. 2010;54(12):5303-5315. doi:10.1128/AAC.00404-10
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. doi:10.1056/NEJMoa1614359
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299-312. doi:10.1038/s41375-018-0357-9
Stansfield LC, Pollyea DA. Midostaurin: a new oral agent targeting FMS-like tyrosine kinase 3-mutant acute myeloid leukemia. Pharmacotherapy. 2017;37(12):1586-1599. doi:10.1002/phar.2039
Kim ES. Midostaurin: first global approval. Drugs. 2017;77(11):1251-1259. doi:10.1007/s40265-017-0779-0
European Medicines Agency. Accessed January 13, 2023. https://www.ema.europa.eu/en/documents/assessment-report/rydapt-epar-public-assessment-report_en.pdf
He H, Tran P, Gu H, et al. Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017;45(5):540-555. doi:10.1124/dmd.116.072744
Gu H, Dutreix C, Rebello S, et al. Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin. Drug Metab Dispos. 2018;46(2):109-121. doi:10.1124/dmd.117.078006
Mancini R, LaMontagne L, Williams T, Kreisle W, Petersen F. Midostaurin and cyclosporine drug interaction: a case report. J Clin Pharm Ther. 2020;45(2):384-387. doi:10.1111/jcpt.13077
Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674-680. doi:10.1345/aph.1H423
Stemler J, Koehler P, Maurer C, Müller C, Cornely OA. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. Ann Hematol. 2020;99(7):1429-1440. doi:10.1007/s00277-020-04107-1
Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to pharmacology 2019/20: G protein-coupled receptors. Br J Pharmacol. 2019;176(Suppl 1):S21-S141.